Board-level credibility
Active audit committee roles plus hands-on operating finance leadership.
About YH
Strategic finance partner for CEOs, boards, and investors.
Senior finance executive with 25+ years in biopharma and growth-stage leadership. Helping teams build sharper financial discipline under pressure.
Currently
Board Member
TesoRx & Lipac Oncology
~600%
Market cap support
MannKind tenure
$17B
Planning scope
BMS business unit
150+
FP&A community
Global capability build
25+
Years
Finance leadership
Why YH
Experience that moves at your pace.
Operator + strategist
Strong in planning architecture and day-to-day execution discipline.
Global scale
U.S., Europe, and Middle East leadership in regulated biopharma.
Data-driven clarity
KPI dashboards and reporting systems built for executive speed.
Career Path
Built in high-stakes environments.
From engineering foundation to board-level finance. Every role sharpened the ability to translate complexity into clear decisions.
2025–Present
Board Member
TesoRx Pharma & Lipac Oncology
Audit and finance oversight for clinical-stage biopharma.
2017–2025
VP Finance
MannKind Corporation
Financial leadership through ~600% market cap growth.
2015–2016
Lead, FP&A Center of Excellence
Bristol Myers Squibb
Built global FP&A community of 150+ professionals.
2011–2015
Director, Corporate FP&A
Bristol Myers Squibb
Long-Term Financial Plan leadership for $17B business scope.
2009–2010
Associate Director Finance – Europe
Bristol Myers Squibb, Paris
EMEA Medicines finance across 30+ markets.
2005–2009
Finance Director Roles
Bristol Myers Squibb, Paris & Cairo
Progressive EMEA leadership in regulated markets.
1994–2004
Financial Analyst to Manager
Bristol Myers Squibb
Foundation in planning, analysis, and systems.
Credentials & Education
MBA
Maastricht School of Management
CPA
California
Languages
English, Arabic (Fluent)
Based in
Oak Park, California
Available for on-site engagements across the U.S. and virtual leadership for global teams.